3-trifluoroacetyl-8-methoxy-2,3,4,5-tetrahydro-1H-3-benzazepine-7-sulfonyl chloride | 571903-31-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯氮卓类
• 英文名称: 3-trifluoroacetyl-8-methoxy-2,3,4,5-tetrahydro-1H-3-benzazepine-7-sulfonyl chloride
• 英文别名: 3-trifluoroacetyl-8-methoxy-1,2,4,5-tetrahvdro-3-benzazepine-7-sulfonyl chloride；8-Methoxy-3-(2,2,2-trifluoroacetyl)-1,2,4,5-tetrahydro-3-benzazepine-7-sulfonyl chloride；8-methoxy-3-(2,2,2-trifluoroacetyl)-1,2,4,5-tetrahydro-3-benzazepine-7-sulfonyl chloride
• CAS: 571903-31-6
• 化学式: C₁₃H₁₃ClF₃NO₄S
• 分子量: 371.765
• InChiKey: LXXTZNFVKDMZND-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  23
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  72.1
• 氢给体数：
  0
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  3-trifluoroacetyl-8-methoxy-2,3,4,5-tetrahydro-1H-3-benzazepine-7-sulfonyl chloride 以80%的产率得到3-trifluoroacetyl-8-methoxy-2,3,4,5-tetrahydro-1H-3-benzazepine-7-sulfonyl fluoride
  参考文献：
  名称：

  [EN] AROMATIC SULFONES AND THEIR MEDICAL USE
  [FR] COMPOSES

  摘要：

  公开号：

  WO2003099786A3
• 作为产物：
  描述：

  7-methoxy-3-(trifluoroacetyl)-2,3,4,5-tetrahydro-1H-3-benzazepine 以85%的产率得到3-trifluoroacetyl-8-methoxy-2,3,4,5-tetrahydro-1H-3-benzazepine-7-sulfonyl chloride
  参考文献：
  名称：

  [EN] AROMATIC SULFONES AND THEIR MEDICAL USE
  [FR] COMPOSES

  摘要：

  公开号：

  WO2003099786A3

文献信息

• [EN] 7-PHENYLSULFONYL-TETRAHYDRO-3-BENZAZEPINE DERIVATIVES AS ANTIPSYCHOTIC AGENTS<br/>[FR] DERIVES DE 7-PHENYLSULFONYL-TETRAHYDRO-3-BENZAZEPINE UTILISES COMME AGENTS ANTIPSYCHOTIQUES
  申请人：GLAXO GROUP LTD

  公开号：WO2003099792A1

  公开（公告）日：2003-12-04

  The invention provides compounds of formula (I): wherein A and B represent the groups -(CH2)m- and -(CH2)n- respectively;R1 represents hydrogen or C1-6alkyl;R2 represents hydrogen, halogen, hydroxy, cyano, nitro, hydroxyC1-6alkyl, trifluoromethyl, trifluoromethoxy, C1-6alkyl, C1-6alkoxy, C1-6fluoroalkoxy, -(CH2)pC3-6cycloalkyl, -(CH2)pOC3-6cycloalkyl, -COC1-6alkyl, -SO2C1-6alkyl, -SOC1-6alkyl, -S-C1-6alkyl, -CO2C1-6alkyl, -CO2NR5R6, -SO2NR5R6, -(CH2)pNR5R6, -(CH2)pNR5COR6, optionally substituted aryl ring, optionally substituted heteroaryl ring or optionally substituted heterocyclyl ring;R3 represents hydrogen, halogen, hydroxy, cyano, nitro, hydroxyC1-6alkyl, trifluoromethyl, trifluoromethoxy, C1-6alkyl, C1-6alkoxy, C1-6fluoroalkoxy, -(CH2)pC3-6cycloalkyl, -(CH2)pOC3-6cycloalkyl, -COC1-6alkyl, -SO2C1-6alkyl, -SOC1-6alkyl, -S-C1-6alkyl, -CO2C1-6alkyl, -CO2NR7R8, -SO2NR7R8, -(CH2)pNR7R8 or -(CH2)pNR7COR8;R4 represents hydrogen, hydroxy, C1-6alkyl, C1-6alkoxy, C1-6fluoroalkoxy, trifluoromethyl, trifluoromethoxy, halogen, -OSO2CF3, -(CH2)pC3-6cycloalkyl, -(CH2)qOC1-6alkyl or -(CH2)pOC3-6cycloalkyl;R5 and R6 each independently represent hydrogen, C1-6alkyl or, together with the nitrogen or other atoms to which they are attached, form an azacycloalkyl ring or an oxo-substituted azacycloalkyl ring;R7 and R8 each independently represent hydrogen or C1-6alkyl;m and n independently represent an integer selected from 1 and 2;p independently represents an integer selected from 0, 1, 2 and 3; q independently represents an integer selected from 1, 2 and 3; or a pharmaceutically acceptable salt or solvate thereof,with the proviso that the compounds 8-hydroxy-3-methyl-7-phenylsulfonyl-2,3,4,5-tetrahydro-1H-3-benzazepine, 8-hydroxy-7-4-(hydroxyphenyl)sulfonyl-2,3,4,5-tetrahydro-1H-3-benzazepine, 7-phenylsulfonyl-1,2,3,4-tetrahydroisoquinoline and 7-phenylsulfonyl-1,2,3,4-tetrahydroisoquinoline hydrochloride are excluded.The compounds are useful in therapy, in particular as antipsychotic agents.

  本发明提供式（I）的化合物：其中A和B分别表示基团-（CH2）m-和-（CH2）n-；R1表示氢或C1-6烷基；R2表示氢，卤素，羟基，氰基，硝基，羟基C1-6烷基，三氟甲基，三氟甲氧基，C1-6烷基，C1-6烷氧基，C1-6氟烷氧基，-（CH2）pC3-6环烷基，-（CH2）pOC3-6环烷基，-COC1-6烷基，-SO2C1-6烷基，-SOC1-6烷基，-S-C1-6烷基，-CO2C1-6烷基，-CO2NR5R6，-SO2NR5R6，-（CH2）pNR5R6，-（CH2）pNR5COR6，可选择取代的芳环，可选择取代的杂环或可选择取代的杂环基；R3表示氢，卤素，羟基，氰基，硝基，羟基C1-6烷基，三氟甲基，三氟甲氧基，C1-6烷基，C1-6烷氧基，C1-6氟烷氧基，-（CH2）pC3-6环烷基，-（CH2）pOC3-6环烷基，-COC1-6烷基，-SO2C1-6烷基，-SOC1-6烷基，-S-C1-6烷基，-CO2C1-6烷基，-CO2NR7R8，-SO2NR7R8，-（CH2）pNR7R8或-（CH2）pNR7COR8；R4表示氢，羟基，C1-6烷基，C1-6烷氧基，C1-6氟烷氧基，三氟甲基，三氟甲氧基，卤素，-OSO2CF3，-（CH2）pC3-6环烷基，-（CH2）qOC1-6烷基或-（CH2）pOC3-6环烷基；R5和R6各自独立地表示氢，C1-6烷基或与它们附着的氮或其他原子一起形成氮杂环烷基环或氧代取代的氮杂环烷基环；R7和R8各自独立地表示氢或C1-6烷基；m和n各自独立地表示选自1和2的整数；p独立地表示选自0，1，2和3的整数；q独立地表示选自1，2和3的整数；或其药学上可接受的盐或溶剂，但排除8-羟基-3-甲基-7-苯基磺酰基-2,3,4,5-四氢-1H-3-苯并噁唑，8-羟基-7-4-（羟基苯基）磺酰基-2,3,4,5-四氢-1H-3-苯并噁唑，7-苯基磺酰基-1,2,3,4-四氢异喹啉和7-苯基磺酰基-1,2,3,4-四氢异喹啉盐酸盐。该化合物在治疗中有用，特别是作为抗精神病药物。
• 7-Phenylsulfonyl-tetrahydro-3-benzazepine derivatives as antipsychotic agents
  申请人：Forbes Thomson Ian

  公开号：US20050245507A1

  公开（公告）日：2005-11-03

  The invention provides compounds of formula (I): wherein A and B represent the groups —(CH 2 ) m — and —(CH 2 ) n — respectively; R 1 represents hydrogen or C 1-6 alkyl; R 2 represents hydrogen, halogen, hydroxy, cyano, nitro, hydroxyC 1-6 alkyl, trifluoromethyl, trifluoromethoxy, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 fluoroalkoxy, —(CH 2 ) p C 3-6 cycloalkyl, —(CH 2 ) p OC 3-6 cycloalkyl, —COC 1-6 alkyl, —SO 2 C 1-6 alkyl, —SOC 1-6 alkyl, —S—C 1-6 alkyl, —CO 2 C 1-6 alkyl, —CO 2 NR 5 R 6 , —SO 2 NR 5 R 6 , —(CH 2 ) p NR 5 R 6 , —(CH 2 ) p NR 5 COR 6 , optionally substituted aryl ring, optionally substituted heteroaryl ring or optionally substituted heterocyclyl ring; R 3 represents hydrogen, halogen, hydroxy, cyano, nitro, hydroxyC 1-6 alkyl, trifluoromethyl, trifluoromethoxy, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 fluoroalkoxy, —(CH 2 ) p C 3-6 cycloalkyl, —(CH 2 ) p OC 3-6 cycloalkyl, —COC 1-6 alkyl, —SO 2 C 1-6 alkyl, —SOC 1-6 alkyl, —S—C 1-6 alkyl, —CO 2 C 1-6 alkyl, —CO 2 NR 7 R 8 , —SO 2 NR 7 R 8 , —(CH 2 ) p NR 7 R 8 or —(CH 2 ) p NR 7 COR 8 ; R 4 represents hydrogen, hydroxy, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 fluoroalkoxy, trifluoromethyl, trifluoromethoxy, halogen, —OSO 2 CF 3 , —(CH 2 ) p C 3-6 cycloalkyl, —(CH 2 ) q OC 1-6 alkyl or —(CH 2 ) p OC 3-6 cycloalkyl; R 5 and R 6 each independently represent hydrogen, C 1-6 alkyl or, together with the nitrogen or other atoms to which they are attached, form an azacycloalkyl ring or an oxo-substituted azacycloalkyl ring; R 7 and R 8 each independently represent hydrogen or C 1-6 alkyl; m and n independently represent an integer selected from 1 and 2; p independently represents an integer selected from 0, 1, 2 and 3; q independently represents an integer selected from 1, 2 and 3; or a pharmaceutically acceptable salt or solvate thereof, with the proviso that the compounds 8-hydroxy-3-methyl-7-phenylsulfonyl-2,3,4,5-tetrahydro-1H-3-benzazepine, 8-hydroxy-7-4-(hydroxyphenyl)sulfonyl-2,3,4,5-tetrahydro-1H-3-benzazepine, 7-phenylsulfonyl-1,2,3,4-tetrahydroisoquinoline and 7-phenylsulfonyl-1,2,3,4-tetrahydroisoquinoline hydrochloride are excluded. The compounds are useful in therapy, in particular as antipsychotic agents.

  该发明提供了式（I）的化合物： 其中，A和B分别表示基团—（CH2）m—和—（CH2）n—； R1表示氢或C1-6烷基； R2表示氢、卤素、羟基、氰基、硝基、羟基C1-6烷基、三氟甲基、三氟甲氧基、C1-6烷基、C1-6烷氧基、C1-6氟烷氧基、—（CH2）pC3-6环烷基、—（CH2）pOC3-6环烷基、—COC1-6烷基、—SO2C1-6烷基、—SOC1-6烷基、—S—C1-6烷基、—CO2C1-6烷基、—CO2NR5R6、—SO2NR5R6、—（CH2）pNR5R6、—（CH2）pNR5COR6、可选择的取代芳环、可选择的取代杂芳环或可选择的取代杂环基； R3表示氢、卤素、羟基、氰基、硝基、羟基C1-6烷基、三氟甲基、三氟甲氧基、C1-6烷基、C1-6烷氧基、C1-6氟烷氧基、—（CH2）pC3-6环烷基、—（CH2）pOC3-6环烷基、—COC1-6烷基、—SO2C1-6烷基、—SOC1-6烷基、—S—C1-6烷基、—CO2C1-6烷基、—CO2NR7R8、—SO2NR7R8、—（CH2）pNR7R8或—（CH2）pNR7COR8； R4表示氢、羟基、C1-6烷基、C1-6烷氧基、C1-6氟烷氧基、三氟甲基、三氟甲氧基、卤素、—OSO2CF3、—（CH2）pC3-6环烷基、—（CH2）qOC1-6烷基或—（CH2）pOC3-6环烷基； R5和R6分别独立地表示氢、C1-6烷基或与它们连接的氮或其他原子一起形成氮杂环烷基或氧代取代的氮杂环烷基环； R7和R8分别独立地表示氢或C1-6烷基； m和n分别独立地表示选自1和2的整数； p独立地表示选自0、1、2和3的整数； q独立地表示选自1、2和3的整数； 或其药学上可接受的盐或溶剂，但排除8-羟基-3-甲基-7-苯基磺酰基-2,3,4,5-四氢-1H-3-苯并哌嗪、8-羟基-7-4-（羟基苯基）磺酰基-2,3,4,5-四氢-1H-3-苯并哌嗪、7-苯基磺酰基-1,2,3,4-四氢异喹啉和7-苯基磺酰基-1,2,3,4-四氢异喹啉盐酸盐化合物。该化合物在治疗中有用，特别是作为抗精神病药物。
• Compounds
  申请人：Forbes Thomson Ian

  公开号：US20050261279A1

  公开（公告）日：2005-11-24

  The invention provides compounds of formula (I): wherein A and B represent the groups —(CH 2 ) m — and —(CH 2 ) n — respectively; R 1 represents hydrogen or C 1-6 alkyl; R 2 represents hydrogen, halogen, hydroxy, cyano, nitro, hydroxy C 1-6 alkyl, trifluoromethyl, trifluoromethoxy, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 fluoroalkoxy, —(CH 2 ) p C 3-6 cycloalkyl, —(CH 2 ) p OC 3-6 cycloalkyl, —COC 1-6 alkyl, —SO 2 C 1-6 alkyl, —SOC 1-6 alkyl, —S—C 1-6 alkyl, —CO 2 C 1-6 alkyl, —CO 2 NR 5 R 6 , —SO 2 NR 5 R 6 , —(CH 2 ) p NR 5 R 6 , —(CF) p NR 5 COR 6 , optionally substituted aryl ring, optionally substituted heteroaryl ring or optionally substituted heterocyclyl ring; R 3 represents optionally substituted aryl ring or optionally substituted heteroaryl ring; R 4 represents hydrogen, hydroxy, C 1-6 alkyl, C 1-6 alkoxy, trifluoromethyl, trifluoromethoxy, halogen, —OSO 2 CF 3 , —(CH 2 ) p C 3-6 cycloalkyl, —(CH 2 ) q OC 1-6 alkyl or —(CH 2 ) p OC 3-6 cycloalkyl; R 5 and R 6 each independently represent hydrogen, C 1-6 alkyl or, together with the nitrogen or other atoms to which they are attached, form an azacycloalkyl ring or an oxo-substituted azacycloalkyl ring; Z represents —(CH 2 ) r X— wherein the —(CH 2 ) r — group is attached to R 3 , or —X(CH 2 ) r — wherein X is attached to R 3 , and wherein any of the —CH 2 — groups may be optionally substituted by one or more C 1-6 alkyl groups; X represents oxygen, —NR 7 or —CH 2 — wherein the —CH 2 — group may be optionally substituted by one or more C 1-6 alkyl groups; R 7 represents hydrogen or C 1-6 alkyl; m and n independently represent an integer selected from 1 and 2; p independently represents an integer selected from 0, 1, 2 and 3; q independently represents an integer selected from 1, 2 and 3; r independently represents an integer selected from 0, 1, and 2; or a pharmaceutically acceptable salt or solvate thereof. The compounds are useful in therapy, in particular as antipsychotic agents.

  本发明提供了式（I）的化合物： 其中，A和B分别代表基团—（CH2）m—和—（CH2）n—；R1代表氢或C1-6烷基；R2代表氢、卤素、羟基、氰基、硝基、羟基C1-6烷基、三氟甲基、三氟甲氧基、C1-6烷基、C1-6烷氧基、C1-6氟烷氧基、—（CH2）pC3-6环烷基、—（CH2）pOC3-6环烷基、—COC1-6烷基、—SO2C1-6烷基、—SOC1-6烷基、—S—C1-6烷基、—CO2C1-6烷基、—CO2NR5R6、—SO2NR5R6、—（CH2）pNR5R6、—（CF）pNR5COR6、可选地取代的芳环、可选地取代的杂芳环或可选地取代的杂环基；R3代表可选地取代的芳环或可选地取代的杂芳环；R4代表氢、羟基、C1-6烷基、C1-6烷氧基、三氟甲基、三氟甲氧基、卤素、—OSO2CF3、—（CH2）pC3-6环烷基、—（CH2）qOC1-6烷基或—（CH2）pOC3-6环烷基；R5和R6各自独立地代表氢、C1-6烷基或与它们所连接的氮或其他原子一起形成氮杂环烷基或氧代取代的氮杂环烷基；Z代表—（CH2）rX—，其中—（CH2）r—基团连接到R3，或—X（CH2）r—，其中X连接到R3，其中任何一个—CH2—基团可以可选地被一个或多个C1-6烷基基团取代；X代表氧、—NR7或—CH2—，其中—CH2—基团可以可选地被一个或多个C1-6烷基基团取代；R7代表氢或C1-6烷基；m和n独立地代表选自1和2的整数；p独立地代表选自0、1、2和3的整数；q独立地代表选自1、2和3的整数；r独立地代表选自0、1和2的整数；或其药学上可接受的盐或溶剂。这些化合物在治疗中有用，特别是作为抗精神病药物。
• 7-sulfonyl-3-benzazepine derivatives as modulators of the dopamine receptor and their use for the treatment cns disorders
  申请人：Ahmed Mahmood

  公开号：US20050176759A1

  公开（公告）日：2005-08-11

  Invented are non-peptide TPO mimetics. Also invented is a method of treating thrombocytopenia, in a mammal, including a human, in need thereof which comprises administering to such mammal an effective amount of a selected hydroxy-1-azobenzene derivative.

  发明了非肽类TPO模拟剂。还发明了一种治疗血小板减少症的方法，包括在需要的哺乳动物，包括人类中，向这种哺乳动物施用所选羟基-1-偶氮苯衍生物的有效量。
• AROMATIC SULFONES AND THEIR MEDICAL USE
  申请人：Forbes Ian Thomson

  公开号：US20080269197A1

  公开（公告）日：2008-10-30

  The invention provides compounds of formula (I): wherein A and B represent the groups —(CH 2 ) m — and —(CH 2 ) n — respectively; R 1 represents hydrogen or C 1-6 alkyl; R 2 represents hydrogen, halogen, hydroxy, cyano, nitro, hydroxy C 1-6 alkyl, trifluoromethyl, trifluoromethoxy, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 fluoroalkoxy, —(CH 2 ) p C 3-6 cycloalkyl, —(CH 2 ) p OC 3-6 cycloalkyl, —COC 1-6 alkyl, —SO 2 C 1-6 alkyl, —SOC 1-6 alkyl, —S—C 1-6 alkyl, —CO 2 C 1-6 alkyl, —CO 2 NR 5 R 6 , —SO 2 NR 5 R 6 , —(CH 2 ) p NR 5 R 6 , —(CH 2 ) p NR 5 COR 6 , optionally substituted aryl ring, optionally substituted heteroaryl ring or optionally substituted heterocyclyl ring; R 3 represents optionally substituted aryl ring or optionally substituted heteroaryl ring; R 4 represents hydrogen, hydroxy, C 1-6 alkyl, C 1-6 alkoxy, trifluoromethyl, trifluoromethoxy, halogen, —OSO 2 CF 3 , —(CH 2 ) p C 3-6 cycloalkyl, —(CH 2 ) q OC 1-6 alkyl or —(CH 2 ) p OC 3-6 cycloalkyl; R 5 and R 6 each independently represent hydrogen, C 1-6 alkyl or, together with the nitrogen or other atoms to which they are attached, form an azacycloalkyl ring or an oxo-substituted azacycloalkyl ring; Z represents —(CH 2 ) r X— wherein the —(CH 2 ) r — group is attached to R 3 , or —X(CH 2 ) r — wherein X is attached to R 3 , and wherein any of the —CH 2 — groups may be optionally substituted by one or more C 1-6 alkyl groups; X represents oxygen, —NR 7 or —CH 2 — wherein the —CH 2 — group may be optionally substituted by one or more C 1-6 alkyl groups; R 7 represents hydrogen or C 1-6 alkyl; m and n independently represent an integer selected from 1 and 2; p independently represents an integer selected from 0, 1, 2 and 3; q independently represents an integer selected from 1, 2 and 3; r independently represents an integer selected from 0, 1, and 2; or a pharmaceutically acceptable salt or solvate thereof. The compounds are useful in therapy, in particular as antipsychotic agents.

  本发明提供了式（I）的化合物：其中A和B分别代表基团-（CH2）m-和-（CH2）n-；R1代表氢或C1-6烷基；R2代表氢、卤素、羟基、氰基、硝基、羟基C1-6烷基、三氟甲基、三氟甲氧基、C1-6烷基、C1-6烷氧基、C1-6氟烷氧基、-（CH2）pC3-6环烷基、-（CH2）pOC3-6环烷基、-COC1-6烷基、-SO2C1-6烷基、-SOC1-6烷基、-S-C1-6烷基、-CO2C1-6烷基、-CO2NR5R6、-SO2NR5R6、-（CH2）pNR5R6、-（CH2）pNR5COR6、可选择取代的芳环、可选择取代的杂芳环或可选择取代的杂环烷基；R3代表可选择取代的芳环或可选择取代的杂芳环；R4代表氢、羟基、C1-6烷基、C1-6烷氧基、三氟甲基、三氟甲氧基、卤素、-OSO2CF3、-（CH2）pC3-6环烷基、-（CH2）qOC1-6烷基或-（CH2）pOC3-6环烷基；R5和R6各自独立地代表氢、C1-6烷基或与它们所附着的氮或其他原子一起形成一个氮杂环烷基或氧代取代的氮杂环烷基；Z代表-（CH2）rX-，其中-（CH2）r-基团附着在R3上，或-X（CH2）r-，其中X附着在R3上，并且任何-CH2-基团都可以选择地被一个或多个C1-6烷基取代；X代表氧、-NR7或-CH2-，其中-CH2-基团可以选择地被一个或多个C1-6烷基取代；R7代表氢或C1-6烷基；m和n分别独立地代表选自1和2的整数；p独立地代表选自0、1、2和3的整数；q独立地代表选自1、2和3的整数；r独立地代表选自0、1和2的整数；或其药学上可接受的盐或溶剂。这些化合物在治疗中有用，特别是作为抗精神病药物。